MX385322B - Uso de sedoheptulosa para la prevención y tratamiento de inflamación. - Google Patents

Uso de sedoheptulosa para la prevención y tratamiento de inflamación.

Info

Publication number
MX385322B
MX385322B MX2015013378A MX2015013378A MX385322B MX 385322 B MX385322 B MX 385322B MX 2015013378 A MX2015013378 A MX 2015013378A MX 2015013378 A MX2015013378 A MX 2015013378A MX 385322 B MX385322 B MX 385322B
Authority
MX
Mexico
Prior art keywords
sedoheptulose
inflammation
prevention
treatment
discloses
Prior art date
Application number
MX2015013378A
Other languages
English (en)
Other versions
MX2015013378A (es
Inventor
Arvand Haschemi
Csörsz Nagy
Oswald Wagner
Rodrig Marculescu
Original Assignee
C7 Sugar Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C7 Sugar Gmbh filed Critical C7 Sugar Gmbh
Publication of MX2015013378A publication Critical patent/MX2015013378A/es
Publication of MX385322B publication Critical patent/MX385322B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La presente invención se refiere a sedoheptulosa para usarse en la prevención o tratamiento de inflamación.
MX2015013378A 2013-03-21 2014-03-21 Uso de sedoheptulosa para la prevención y tratamiento de inflamación. MX385322B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13160443.1A EP2781219A1 (en) 2013-03-21 2013-03-21 Use of sedoheptulose for prevention or treatment of inflammation
PCT/EP2014/055679 WO2014147214A1 (en) 2013-03-21 2014-03-21 Use of sedoheptulose for prevention or treatment of inflammation

Publications (2)

Publication Number Publication Date
MX2015013378A MX2015013378A (es) 2016-01-08
MX385322B true MX385322B (es) 2025-03-18

Family

ID=47901873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013378A MX385322B (es) 2013-03-21 2014-03-21 Uso de sedoheptulosa para la prevención y tratamiento de inflamación.

Country Status (16)

Country Link
US (2) US9694026B2 (es)
EP (2) EP2781219A1 (es)
JP (1) JP6388635B2 (es)
CN (2) CN105283188A (es)
AU (1) AU2014234230B2 (es)
BR (1) BR112015023463A2 (es)
CA (1) CA2903151C (es)
DK (1) DK2976089T3 (es)
ES (1) ES2930249T3 (es)
HU (1) HUE060237T2 (es)
MX (1) MX385322B (es)
NZ (1) NZ711523A (es)
PL (1) PL2976089T3 (es)
PT (1) PT2976089T (es)
WO (1) WO2014147214A1 (es)
ZA (1) ZA201506396B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2781218A1 (en) 2013-03-21 2014-09-24 Medizinische Universität Wien Use of sedoheptulose as a nutritional supplement
CN106309458A (zh) * 2016-07-28 2017-01-11 中南大学湘雅医院 2‑脱氧‑d‑葡萄糖及其在药学上可接受的盐在制备治疗银屑病药物方面的应用
CN116602363B (zh) * 2023-06-17 2025-01-24 广东驱动力生物科技集团股份有限公司 一种治疗或预防肉食性鱼脂肪肝的助剂及其制备方法
CN119405681B (zh) * 2024-11-04 2025-09-23 新乡医学院 核糖-5磷酸在制备治疗炎症性疾病药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE78166T1 (de) 1985-10-22 1992-08-15 Silvetti Anthony N Monosaccharide enthaltende zusammensetzung zum heilen von wunden.
JPH04335877A (ja) 1991-05-13 1992-11-24 Eimu:Kk 十薬食品・飲料並びに製造法
US9492582B2 (en) * 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20090252834A1 (en) 2004-05-10 2009-10-08 Michael Griffin Hayek Compositions comprising glucose anti-metabolites
BRPI0513670A (pt) 2004-07-30 2008-05-13 Pharmed Medicare Pty Ltd composição adoçante de calorias reduzidas
CA2599011A1 (en) 2005-02-28 2006-09-08 Mcneil Nutritionals, Llc Brown sugar substitute
JP5048238B2 (ja) 2005-11-16 2012-10-17 エスエス製薬株式会社 ウワウルシ乾燥エキス含有経口製剤
GB0720516D0 (en) 2007-10-18 2007-11-28 Cadbury Schweppes Plc Comestible products
KR100912277B1 (ko) * 2007-11-21 2009-08-17 한국생명공학연구원 내열성 효소를 이용하여 세도헵툴로스를 제조하는 방법
CN101919872B (zh) * 2010-07-21 2011-12-07 广东粤龙药业有限公司 景酮糖酐在制备抗乙肝药物中的应用
GB201303698D0 (en) 2012-10-26 2013-04-17 Tate & Lyle Ingredients Sweetener syrups
CN103059071B (zh) * 2013-01-08 2016-03-16 华东理工大学 一种单糖的纳滤分离方法
EP2781218A1 (en) 2013-03-21 2014-09-24 Medizinische Universität Wien Use of sedoheptulose as a nutritional supplement

Also Published As

Publication number Publication date
WO2014147214A1 (en) 2014-09-25
ZA201506396B (en) 2018-05-30
CA2903151A1 (en) 2014-09-25
CA2903151C (en) 2021-11-30
US20170281661A1 (en) 2017-10-05
US20160045525A1 (en) 2016-02-18
JP6388635B2 (ja) 2018-09-12
EP2976089A1 (en) 2016-01-27
AU2014234230A1 (en) 2015-09-17
US9694026B2 (en) 2017-07-04
PL2976089T3 (pl) 2023-01-30
EP2781219A1 (en) 2014-09-24
JP2016516077A (ja) 2016-06-02
MX2015013378A (es) 2016-01-08
AU2014234230B2 (en) 2018-08-09
US10660910B2 (en) 2020-05-26
DK2976089T3 (da) 2022-11-07
NZ711523A (en) 2020-09-25
BR112015023463A2 (pt) 2017-07-18
PT2976089T (pt) 2022-11-22
HUE060237T2 (hu) 2023-02-28
CN115364112A (zh) 2022-11-22
EP2976089B1 (en) 2022-08-17
ES2930249T3 (es) 2022-12-09
CN105283188A (zh) 2016-01-27

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
MY176285A (en) Anti-fcrh5 antibodies
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
PL3464368T3 (pl) Zastosowanie przeciwciała anty-pd-1 w skojarzeniu z przeciwciałem anty-cd30 w leczeniu chłoniaka
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
SI3189074T1 (sl) Sestavki in postopki za zdravljenje in preprečevanje vnetja
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
BR112016027043A2 (pt) Combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
IL247435A0 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
PH12016501838A1 (en) Compounds and their methods of use
MX2015013378A (es) Uso de sedoheptulosa para la prevencion y tratamiento de inflamacion.
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
PL3630112T3 (pl) Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu
IL311363A (en) Compositions for use in treating cognitive impairment
PT3383381T (pt) Composto para uso na prevenção e tratamento de doenças neurodegenerativas
AU355724S (en) Tensioner bracket